Drug Pricing Reform In Medicare And Medicaid: Upcoming Regulatory Actions
Two highly anticipated proposed rules in Medicare Part D are scheduled for near-term release.
You may also be interested in...
Congressional inaction on drug pricing legislation has meant the Trump Administration is pursuing a menu of regulatory approaches. For the most part, that means slower and incremental change.
President Trump is highlighting drug pricing as an area where he may be able to work with the new Democratic majority in the House. The political wisdom of building common ground on the topic is hard to ignore – but the tempestuous personality of the President is still the overriding factor. Instead, focus on whether HHS can win some breathing room to keep going with administrative changes.
Approach offered as alternative to more disruptive changes to Part B's existing buy-and-bill system; more aggressive proposals include new iteration of competitive acquisition program and moving Part B drug coverage to Part D.